Applications are sought for the position of post-doctoral research fellow to work on an exciting inter-disciplinary research project concerning the discovery of novel drugs against GU cancers and translation of the laboratory findings to clinic at Moffitt. We seek a talented individual with a PhD and background in cell biology, biochemistry, molecular biology and drug discovery. The unique research environment includes state of the art modern molecular and cellular biology as well as in silico and experimental high through put screening and other drug discovery facilities.

In addition to experience in molecular biology, the successful candidate will have experience in vitro and in vivo assay development as it relates to drug discovery as well as demonstrated creativity, high motivation, good communication skills and importantly, experience in developing/writing publications. They should possess the ability to work independently and within the research group. A good understanding of biology and a track record in working closely with experimentalists and clinicians is preferred.

Additional Information: Examples of projects that the candidate will be performing and responsible for are:

1. To determine the ability of AJI-214 (dual Jak/Aurora Kinase inhibitor) alone and in combination with anti-androgens and chemotherapeutic agents to modulate signaling and to inhibit proliferation and invasion and to induce apoptosis in prostate cancer cells in vitro and in xenografts.

2. To determine the ability of S3I-201 (STAT3 inhibitor) alone and in combination with Gemcitabine and cisplatin in bladder and Taxotere in prostate cancer cell lines and xenografts. The focus will be on prostate and bladder cancer cell lines that have hyper – activated constitutively Tyrosine phosphorylated STAT3.

3. To test the hypothesis that bladder and prostate cancer cells that express low levels of the CDK inhibitor p27 will be more sensitive to GGTI-2418 (Geranylgeranyltransferase I inhibitor).

4. To test the hypothesis that bladder cancer cells with H-Ras mutations will be more sensitive to tipifarnib (Farnesyltarnsferase inhibitor (FTI)).

5. To determine the ability of TCN-P (Akt inhibitor) alone and in combination with novel hormonal agents like abiraterone and enzaluatmide in prostate cancer cell lines that have hyper – activated constitutively phosphorylated Akt.

The drug discovery and GU Departments are housed within the H. Lee Moffitt Comprehensive Cancer Center which is a modern facility on the University of South Florida Campus that conducts research on various aspects of Cancer Biology with emphasis on translational research. Investigators for this project are Dr. Said Sebti, Dr. Julio Pow Sang, and Dr. Shilpa Gupta.

Please visit www.moffitt.org/careers and apply to Req ID # 9956, making sure to attach a CV, a brief summary of research experience and career goals, and contact information for three professional/academic references.

H. Lee Moffitt Cancer Center & Research Institute is an equal opportunity, affirmative action employer, and a drug free workplace

中国-博士人才网发布